Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial.

Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais JP.

Thorax. 2006 Oct;61(10):895-902. Epub 2006 Jun 29.

2.

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Anstead M, Mayer-Hamblett N, Lands LC, Kloster M, Hocevar-Trnka J, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Azithromycin Study Group..

JAMA. 2010 May 5;303(17):1707-15. doi: 10.1001/jama.2010.563.

PMID:
20442386
3.

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.

Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW 3rd; Macrolide Study Group..

JAMA. 2003 Oct 1;290(13):1749-56.

PMID:
14519709
4.

Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.

Wong C, Jayaram L, Karalus N, Eaton T, Tong C, Hockey H, Milne D, Fergusson W, Tuffery C, Sexton P, Storey L, Ashton T.

Lancet. 2012 Aug 18;380(9842):660-7. doi: 10.1016/S0140-6736(12)60953-2.

PMID:
22901887
5.

Macrolide antibiotics for cystic fibrosis.

Southern KW, Barker PM, Solis-Moya A, Patel L.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD002203. doi: 10.1002/14651858.CD002203.pub4. Review.

PMID:
23152214
6.

Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial.

Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J.

Thorax. 2002 Mar;57(3):212-6.

7.

Macrolide antibiotics for cystic fibrosis.

Southern KW, Barker PM, Solis-Moya A, Patel L.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD002203. doi: 10.1002/14651858.CD002203.pub3. Review. Update in: Cochrane Database Syst Rev. 2012;11:CD002203.

PMID:
22161368
8.

Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.

Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S.

Respir Med. 2008 Nov;102(11):1643-53. doi: 10.1016/j.rmed.2008.03.009. Epub 2008 Aug 12.

9.

The use of macrolide antibiotics in patients with cystic fibrosis.

Saiman L.

Curr Opin Pulm Med. 2004 Nov;10(6):515-23. Review.

PMID:
15510060
10.

Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa.

Saiman L, Mayer-Hamblett N, Anstead M, Lands LC, Kloster M, Goss CH, Rose LM, Burns JL, Marshall BC, Ratjen F; AZ0004 Macrolide Study Team..

Pediatr Pulmonol. 2012 Jul;47(7):641-8. doi: 10.1002/ppul.21601. Epub 2012 Jan 3.

PMID:
22684984
11.

Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.

Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC; Macrolide Study Group..

Am J Respir Crit Care Med. 2005 Oct 15;172(8):1008-12. Epub 2005 Jul 22.

PMID:
16040785
12.

Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial.

Equi A, Balfour-Lynn IM, Bush A, Rosenthal M.

Lancet. 2002 Sep 28;360(9338):978-84.

PMID:
12383667
13.

Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.

Pirzada OM, McGaw J, Taylor CJ, Everard ML.

J Cyst Fibros. 2003 Jun;2(2):69-71.

14.

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.

Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, Malfroot A, Rosenbluth DB, Walker PA, McColley SA, Knoop C, Quattrucci S, Rietschel E, Zeitlin PL, Barth J, Elfring GL, Welch EM, Branstrom A, Spiegel RJ, Peltz SW, Ajayi T, Rowe SM; Cystic Fibrosis Ataluren Study Group..

Lancet Respir Med. 2014 Jul;2(7):539-47. doi: 10.1016/S2213-2600(14)70100-6. Epub 2014 May 15.

15.

Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.

Valery PC, Morris PS, Byrnes CA, Grimwood K, Torzillo PJ, Bauert PA, Masters IB, Diaz A, McCallum GB, Mobberley C, Tjhung I, Hare KM, Ware RS, Chang AB.

Lancet Respir Med. 2013 Oct;1(8):610-20. doi: 10.1016/S2213-2600(13)70185-1. Epub 2013 Sep 17. Erratum in: Lancet Respir Med. 2015 Aug;3(8):e29.

PMID:
24461664
16.

Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.

Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ, van der Werf TS, Boersma WG.

JAMA. 2013 Mar 27;309(12):1251-9. doi: 10.1001/jama.2013.1937.

PMID:
23532241
17.

Long term azithromycin therapy in patients with cystic fibrosis.

Emiralioğlu N, Öztürk Z, Yalçın E, Doğru D, Özçelik U, Kiper N.

Turk J Pediatr. 2016;58(1):34-40.

18.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2014 Nov 10;(11):CD004197. doi: 10.1002/14651858.CD004197.pub4. Review.

PMID:
25383937
19.
20.

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S, Smith AL.

N Engl J Med. 1999 Jan 7;340(1):23-30.

Supplemental Content

Support Center